Fibrinogen Replacement Therapy Outlook: Congenital Deficiencies, Surgical Hemostasis
公開 2026/04/01 17:50
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fibrinogen for Injection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fibrinogen for Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hematologists, anesthesiologists, and critical care physicians, managing acute bleeding episodes in patients with fibrinogen deficiency represents a high-stakes clinical challenge where timely intervention directly impacts patient outcomes. Fibrinogen for Injection—a sterile, lyophilized plasma-derived product—provides a targeted, fast-acting solution to restore fibrinogen levels and enable effective coagulation in patients with congenital or acquired deficiencies. As surgical volumes increase, trauma care advances, and awareness of bleeding disorders grows, the demand for this essential hemostatic agent is poised for sustained growth, driven by clinical necessity and expanding therapeutic applications.
The global market for Fibrinogen for Injection was estimated to be worth US$ 496 million in 2025 and is projected to reach US$ 802 million, growing at a CAGR of 7.2% from 2026 to 2032. In 2024, global fibrinogen for injection sales reached approximately 3,342 thousand vials, with an average global market price of around US$ 140 per vial. Fibrinogen for Injection is a sterile, lyophilized (freeze-dried) plasma-derived product used to treat acute bleeding episodes in patients with congenital or acquired fibrinogen deficiency. As a critical protein in the blood coagulation cascade, fibrinogen is essential for clot formation and wound healing. This injectable form is reconstituted with sterile water and administered intravenously to rapidly restore fibrinogen levels, helping to control bleeding during surgery, trauma, or in patients with conditions like afibrinogenemia or dysfibrinogenemia. It offers a targeted, fast-acting solution when timely clot formation is crucial for patient outcomes.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6094610/fibrinogen-for-injection
Product Segmentation and Indication-Based Dynamics
The market is segmented by dosage strength into 0.5g/vial and 1.0g/vial formulations. The 1.0g/vial segment accounts for approximately 65% of total market volume in 2024, driven by its preference in adult surgical settings and acute bleeding management where higher fibrinogen replacement doses are typically required.
Industry stratification reveals distinct clinical and operational dynamics across therapeutic applications. Congenital hypofibrinogenemia—including afibrinogenemia and dysfibrinogenemia—represents a stable patient population requiring ongoing management, with treatment focused on prophylactic or on-demand replacement therapy. In contrast, acquired hypofibrinogenemia encompasses a broader, more dynamic patient base including surgical patients, trauma victims, and those with consumptive coagulopathies. According to QYResearch’s clinical utilization tracking data, acquired indications account for approximately 78% of total fibrinogen consumption, driven by the increasing volume of complex surgical procedures and trauma cases requiring acute hemostatic management.
Technical Challenges and Product Innovation
A persistent technical challenge in the fibrinogen for injection market is ensuring product stability and consistency while maintaining viral safety of plasma-derived products. Modern manufacturing processes incorporate multiple viral inactivation steps—including solvent/detergent treatment, nanofiltration, and heat treatment—to ensure pathogen safety while preserving protein integrity.
Recent advancements in manufacturing technology have improved product consistency. A representative case involves a leading manufacturer that implemented enhanced lyophilization cycle optimization in Q1 2025, achieving a 15% reduction in batch-to-batch variability while maintaining full biological activity of the fibrinogen concentrate. According to post-implementation data shared with QYResearch, the optimized process resulted in improved reconstitution time and enhanced stability under accelerated storage conditions.
Regulatory Landscape and Market Access
Regulatory frameworks governing plasma-derived products are among the most stringent in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) require comprehensive validation of donor screening, plasma collection, viral inactivation, and final product testing. The European Pharmacopoeia (Ph. Eur.) monograph for fibrinogen concentrate establishes specific requirements for potency, purity, and safety testing.
Recent regulatory developments have focused on supply chain resilience. Following the COVID-19 pandemic, both FDA and EMA have issued guidance encouraging diversification of plasma sourcing and inventory management to ensure sustained availability of critical hemostatic products. This has prompted several manufacturers to expand plasma collection networks and increase inventory buffers, with QYResearch’s supply chain analysis indicating a 22% increase in average inventory levels across major manufacturers in 2025 compared to 2023.
Exclusive Observation: Emerging Applications and Regional Growth Patterns
A distinctive trend emerging in the fibrinogen for injection market is the expansion beyond traditional congenital deficiency indications into acquired bleeding management across broader surgical and trauma populations. Clinical evidence supporting early fibrinogen replacement in massive transfusion protocols has gained significant traction, with several updated clinical guidelines now recommending fibrinogen concentrate as first-line therapy in trauma-induced coagulopathy.
From a regional perspective, Asia-Pacific is forecast to register the fastest CAGR through 2032, driven by improving healthcare infrastructure, increasing surgical volumes, and growing awareness of bleeding disorder management. According to QYResearch’s regional analysis, the Chinese market—led by domestic manufacturers including Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, and Taibang Biologic—is projected to grow at a CAGR of 9.2%, outpacing global averages. This growth reflects both increasing clinical adoption and continued expansion of domestic plasma collection and fractionation capacity.
Market Segmentation
The Fibrinogen for Injection market is segmented as below:
Segment by Type:
0.5g/Vial
1.0g/Vial
Segment by Application:
Congenital Hypofibrinogenemia
Acquired Hypofibrinogenemia
Key Industry Participants
The market is characterized by a concentrated group of global and regional plasma fractionation specialists:
CSL Behring, LFB Biopharmaceuticals, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, Taibang Biologic, Octapharma.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For hematologists, anesthesiologists, and critical care physicians, managing acute bleeding episodes in patients with fibrinogen deficiency represents a high-stakes clinical challenge where timely intervention directly impacts patient outcomes. Fibrinogen for Injection—a sterile, lyophilized plasma-derived product—provides a targeted, fast-acting solution to restore fibrinogen levels and enable effective coagulation in patients with congenital or acquired deficiencies. As surgical volumes increase, trauma care advances, and awareness of bleeding disorders grows, the demand for this essential hemostatic agent is poised for sustained growth, driven by clinical necessity and expanding therapeutic applications.
The global market for Fibrinogen for Injection was estimated to be worth US$ 496 million in 2025 and is projected to reach US$ 802 million, growing at a CAGR of 7.2% from 2026 to 2032. In 2024, global fibrinogen for injection sales reached approximately 3,342 thousand vials, with an average global market price of around US$ 140 per vial. Fibrinogen for Injection is a sterile, lyophilized (freeze-dried) plasma-derived product used to treat acute bleeding episodes in patients with congenital or acquired fibrinogen deficiency. As a critical protein in the blood coagulation cascade, fibrinogen is essential for clot formation and wound healing. This injectable form is reconstituted with sterile water and administered intravenously to rapidly restore fibrinogen levels, helping to control bleeding during surgery, trauma, or in patients with conditions like afibrinogenemia or dysfibrinogenemia. It offers a targeted, fast-acting solution when timely clot formation is crucial for patient outcomes.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6094610/fibrinogen-for-injection
Product Segmentation and Indication-Based Dynamics
The market is segmented by dosage strength into 0.5g/vial and 1.0g/vial formulations. The 1.0g/vial segment accounts for approximately 65% of total market volume in 2024, driven by its preference in adult surgical settings and acute bleeding management where higher fibrinogen replacement doses are typically required.
Industry stratification reveals distinct clinical and operational dynamics across therapeutic applications. Congenital hypofibrinogenemia—including afibrinogenemia and dysfibrinogenemia—represents a stable patient population requiring ongoing management, with treatment focused on prophylactic or on-demand replacement therapy. In contrast, acquired hypofibrinogenemia encompasses a broader, more dynamic patient base including surgical patients, trauma victims, and those with consumptive coagulopathies. According to QYResearch’s clinical utilization tracking data, acquired indications account for approximately 78% of total fibrinogen consumption, driven by the increasing volume of complex surgical procedures and trauma cases requiring acute hemostatic management.
Technical Challenges and Product Innovation
A persistent technical challenge in the fibrinogen for injection market is ensuring product stability and consistency while maintaining viral safety of plasma-derived products. Modern manufacturing processes incorporate multiple viral inactivation steps—including solvent/detergent treatment, nanofiltration, and heat treatment—to ensure pathogen safety while preserving protein integrity.
Recent advancements in manufacturing technology have improved product consistency. A representative case involves a leading manufacturer that implemented enhanced lyophilization cycle optimization in Q1 2025, achieving a 15% reduction in batch-to-batch variability while maintaining full biological activity of the fibrinogen concentrate. According to post-implementation data shared with QYResearch, the optimized process resulted in improved reconstitution time and enhanced stability under accelerated storage conditions.
Regulatory Landscape and Market Access
Regulatory frameworks governing plasma-derived products are among the most stringent in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) require comprehensive validation of donor screening, plasma collection, viral inactivation, and final product testing. The European Pharmacopoeia (Ph. Eur.) monograph for fibrinogen concentrate establishes specific requirements for potency, purity, and safety testing.
Recent regulatory developments have focused on supply chain resilience. Following the COVID-19 pandemic, both FDA and EMA have issued guidance encouraging diversification of plasma sourcing and inventory management to ensure sustained availability of critical hemostatic products. This has prompted several manufacturers to expand plasma collection networks and increase inventory buffers, with QYResearch’s supply chain analysis indicating a 22% increase in average inventory levels across major manufacturers in 2025 compared to 2023.
Exclusive Observation: Emerging Applications and Regional Growth Patterns
A distinctive trend emerging in the fibrinogen for injection market is the expansion beyond traditional congenital deficiency indications into acquired bleeding management across broader surgical and trauma populations. Clinical evidence supporting early fibrinogen replacement in massive transfusion protocols has gained significant traction, with several updated clinical guidelines now recommending fibrinogen concentrate as first-line therapy in trauma-induced coagulopathy.
From a regional perspective, Asia-Pacific is forecast to register the fastest CAGR through 2032, driven by improving healthcare infrastructure, increasing surgical volumes, and growing awareness of bleeding disorder management. According to QYResearch’s regional analysis, the Chinese market—led by domestic manufacturers including Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, and Taibang Biologic—is projected to grow at a CAGR of 9.2%, outpacing global averages. This growth reflects both increasing clinical adoption and continued expansion of domestic plasma collection and fractionation capacity.
Market Segmentation
The Fibrinogen for Injection market is segmented as below:
Segment by Type:
0.5g/Vial
1.0g/Vial
Segment by Application:
Congenital Hypofibrinogenemia
Acquired Hypofibrinogenemia
Key Industry Participants
The market is characterized by a concentrated group of global and regional plasma fractionation specialists:
CSL Behring, LFB Biopharmaceuticals, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, Taibang Biologic, Octapharma.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ